Gifford Bioscience Limited is a preclinical contract research organization (CRO) providing specialist services in radioligand binding assays, receptor occupancy studies, autoradiography and SPR.
At Gifford Bioscience, we employ “gold standard” radiometric methods, for maximum sensitivity and robustness, together with label-free, kinetic affinity techniques. We use cell membranes, live cells, human tissue and animal tissue.
Determination of receptor affinities and binding parameters for test compounds in a tissue homogenate or cell preparation.
Measurement of the degree to which a test compound engages its target receptor in live cells, tissues or in an animal.
Imaging distribution of a labeled test drug in tissue or organ sections.
Measurement of a compounds transport into cells or efflux from cells. Determination of a compound’s potency and efficacy.
Kinetic, label-fee measurement of a drug’s affinity for its receptor using Surface Plasmon Resonance (SPR).
The virus infects human lung cells through the binding of the SARS-CoV-2 S ‘spike’ protein to the trans-membrane receptor Angiotensin Converting Enzyme 2 (ACE2) expressed on the cells. SPR analysis (Biacore T200) was used to determine the affinity of the spike protein...
Gifford Bioscience is currently operational, prioritising COVID-19 work on the SARS-CoV2 spike protein : ACE2 interaction, using both SPR Biacore and radiometric techniques. The studies are with recombinant protein, live cells and human lung and brain...